BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.
BMRN Key Statistics
Stock Snapshot
With a market cap of 10.67B, BioMarin(BMRN) trades at $55.51. The stock has a price-to-earnings ratio of 31.06.
On 2026-03-18, BioMarin(BMRN) stock moved within a range of $54.82 to $56.50. With shares now at $55.51, the stock is trading +1.2% above its intraday low and -1.8% below the session's peak.
Trading volume for BioMarin(BMRN) stock has reached 1.28M, versus its average volume of 2.06M.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.18 and a low of $50.76.
Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.18 and a low of $50.76.
BMRN News
Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. The ENERGY 2 Study is an open-label Phase 3 trial called “The ENERGY 2...
BioMarin Pharmaceutical (BMRN) is back on investor watch after recent trading left the shares about 20% lower over the past year, despite annual revenue of US$3...
BioMarin (BMRN) announced Monday the discontinuation of three Voxzogo Phase 2 studies in Turner Syndrome, SHOX-difficiency, and ACAN-difficiency, due to several...
Analyst ratings
81%
of 26 ratingsMore BMRN News
BioMarin Pharmaceutical ( (BMRN) ) has issued an announcement. On March 16, 2026, BioMarin announced it would discontinue dosing and enrollment in its Phase 2...
BioMarin (BMRN) announced its decision to discontinue dosing and enrollment in its Phase 2 trials for Voxzogo in Turner syndrome, SHOX-deficiency and aggrecan-d...
BioMarin Pharmaceutical (NasdaqGS:BMRN) reported new multi year data on VOXZOGO in young children with achondroplasia. The results, from clinical and real worl...
New insider activity at BioMarin Pharmaceutical ( (BMRN) ) has taken place on March 12, 2026. EVP and Chief Technology Officer Charles Greg Guyer of BioMarin P...
BioMarin (BMRN) announced positive new data from studies of Voxzogo – vosoritide – in children with achondroplasia in ongoing clinical trials and real-world stu...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.